Chemoradiotherapy for solitary skeletal muscle metastasis from oesophageal cancer: Case report and brief literature review

Yoshiaki Fujimoto, Yuichiro Nakashima, Shun Sasaki, Tomoko Jogo, Kosuke Hirose, Keitaro Edahiro, Shotaro Korehisa, Daisuke Taniguchi, Kensuke Kudou, Yu Nakaji, Ryota Nakanishi, Kouji Andou, Hiroshi Saeki, Eiji Oki, Minako Fujiwara, Yoshinao Oda, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Background: The incidence of skeletal muscle metastasis from oesophageal cancer is very low, and the treatment strategy has not been established. Case Report: A 77-year-old man underwent oesophagectomy following neoadjuvant chemotherapy for oesophageal squamous cell carcinoma (CT-pT3 N0 M0, CT-pStage II). Fourteen months after surgery, he became aware of a subcutaneous tumour in his left forearm. Computed tomography and fluorodeoxyglucose positron-emission tomography revealed a 65×75 mm intramuscular nodular lesion with a standardized uptake value of 8.5. Further examination by biopsy strongly suggested this was a solitary metastasis from oesophageal cancer. The patient received chemoradiotherapy with two cycles of 5- fluorouracil combined with cisplatin and radiation. Clinical complete response was confirmed by imaging 7 months after chemoradiation and no recurrence has occurred at 20 months since chemoradiation. Conclusion: Radiotherapy or chemoradiotherapy can be an alternative locoregional therapy to surgery for solitary skeletal muscle metastasis.

元の言語英語
ページ(範囲)5687-5691
ページ数5
ジャーナルAnticancer research
37
発行部数10
DOI
出版物ステータス出版済み - 10 1 2017

Fingerprint

Chemoradiotherapy
Esophageal Neoplasms
Skeletal Muscle
Neoplasm Metastasis
Esophagectomy
Complementary Therapies
Forearm
Fluorouracil
Cisplatin
Radiotherapy
Radiation
Biopsy
Recurrence
Drug Therapy
Incidence
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Chemoradiotherapy for solitary skeletal muscle metastasis from oesophageal cancer : Case report and brief literature review. / Fujimoto, Yoshiaki; Nakashima, Yuichiro; Sasaki, Shun; Jogo, Tomoko; Hirose, Kosuke; Edahiro, Keitaro; Korehisa, Shotaro; Taniguchi, Daisuke; Kudou, Kensuke; Nakaji, Yu; Nakanishi, Ryota; Andou, Kouji; Saeki, Hiroshi; Oki, Eiji; Fujiwara, Minako; Oda, Yoshinao; Maehara, Yoshihiko.

:: Anticancer research, 巻 37, 番号 10, 01.10.2017, p. 5687-5691.

研究成果: ジャーナルへの寄稿記事

Fujimoto, Y, Nakashima, Y, Sasaki, S, Jogo, T, Hirose, K, Edahiro, K, Korehisa, S, Taniguchi, D, Kudou, K, Nakaji, Y, Nakanishi, R, Andou, K, Saeki, H, Oki, E, Fujiwara, M, Oda, Y & Maehara, Y 2017, 'Chemoradiotherapy for solitary skeletal muscle metastasis from oesophageal cancer: Case report and brief literature review', Anticancer research, 巻. 37, 番号 10, pp. 5687-5691. https://doi.org/10.21873/anticanres.12005
Fujimoto, Yoshiaki ; Nakashima, Yuichiro ; Sasaki, Shun ; Jogo, Tomoko ; Hirose, Kosuke ; Edahiro, Keitaro ; Korehisa, Shotaro ; Taniguchi, Daisuke ; Kudou, Kensuke ; Nakaji, Yu ; Nakanishi, Ryota ; Andou, Kouji ; Saeki, Hiroshi ; Oki, Eiji ; Fujiwara, Minako ; Oda, Yoshinao ; Maehara, Yoshihiko. / Chemoradiotherapy for solitary skeletal muscle metastasis from oesophageal cancer : Case report and brief literature review. :: Anticancer research. 2017 ; 巻 37, 番号 10. pp. 5687-5691.
@article{9a7c39b4a5644689a14e5d7b267b45d9,
title = "Chemoradiotherapy for solitary skeletal muscle metastasis from oesophageal cancer: Case report and brief literature review",
abstract = "Background: The incidence of skeletal muscle metastasis from oesophageal cancer is very low, and the treatment strategy has not been established. Case Report: A 77-year-old man underwent oesophagectomy following neoadjuvant chemotherapy for oesophageal squamous cell carcinoma (CT-pT3 N0 M0, CT-pStage II). Fourteen months after surgery, he became aware of a subcutaneous tumour in his left forearm. Computed tomography and fluorodeoxyglucose positron-emission tomography revealed a 65×75 mm intramuscular nodular lesion with a standardized uptake value of 8.5. Further examination by biopsy strongly suggested this was a solitary metastasis from oesophageal cancer. The patient received chemoradiotherapy with two cycles of 5- fluorouracil combined with cisplatin and radiation. Clinical complete response was confirmed by imaging 7 months after chemoradiation and no recurrence has occurred at 20 months since chemoradiation. Conclusion: Radiotherapy or chemoradiotherapy can be an alternative locoregional therapy to surgery for solitary skeletal muscle metastasis.",
author = "Yoshiaki Fujimoto and Yuichiro Nakashima and Shun Sasaki and Tomoko Jogo and Kosuke Hirose and Keitaro Edahiro and Shotaro Korehisa and Daisuke Taniguchi and Kensuke Kudou and Yu Nakaji and Ryota Nakanishi and Kouji Andou and Hiroshi Saeki and Eiji Oki and Minako Fujiwara and Yoshinao Oda and Yoshihiko Maehara",
year = "2017",
month = "10",
day = "1",
doi = "10.21873/anticanres.12005",
language = "English",
volume = "37",
pages = "5687--5691",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Chemoradiotherapy for solitary skeletal muscle metastasis from oesophageal cancer

T2 - Case report and brief literature review

AU - Fujimoto, Yoshiaki

AU - Nakashima, Yuichiro

AU - Sasaki, Shun

AU - Jogo, Tomoko

AU - Hirose, Kosuke

AU - Edahiro, Keitaro

AU - Korehisa, Shotaro

AU - Taniguchi, Daisuke

AU - Kudou, Kensuke

AU - Nakaji, Yu

AU - Nakanishi, Ryota

AU - Andou, Kouji

AU - Saeki, Hiroshi

AU - Oki, Eiji

AU - Fujiwara, Minako

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: The incidence of skeletal muscle metastasis from oesophageal cancer is very low, and the treatment strategy has not been established. Case Report: A 77-year-old man underwent oesophagectomy following neoadjuvant chemotherapy for oesophageal squamous cell carcinoma (CT-pT3 N0 M0, CT-pStage II). Fourteen months after surgery, he became aware of a subcutaneous tumour in his left forearm. Computed tomography and fluorodeoxyglucose positron-emission tomography revealed a 65×75 mm intramuscular nodular lesion with a standardized uptake value of 8.5. Further examination by biopsy strongly suggested this was a solitary metastasis from oesophageal cancer. The patient received chemoradiotherapy with two cycles of 5- fluorouracil combined with cisplatin and radiation. Clinical complete response was confirmed by imaging 7 months after chemoradiation and no recurrence has occurred at 20 months since chemoradiation. Conclusion: Radiotherapy or chemoradiotherapy can be an alternative locoregional therapy to surgery for solitary skeletal muscle metastasis.

AB - Background: The incidence of skeletal muscle metastasis from oesophageal cancer is very low, and the treatment strategy has not been established. Case Report: A 77-year-old man underwent oesophagectomy following neoadjuvant chemotherapy for oesophageal squamous cell carcinoma (CT-pT3 N0 M0, CT-pStage II). Fourteen months after surgery, he became aware of a subcutaneous tumour in his left forearm. Computed tomography and fluorodeoxyglucose positron-emission tomography revealed a 65×75 mm intramuscular nodular lesion with a standardized uptake value of 8.5. Further examination by biopsy strongly suggested this was a solitary metastasis from oesophageal cancer. The patient received chemoradiotherapy with two cycles of 5- fluorouracil combined with cisplatin and radiation. Clinical complete response was confirmed by imaging 7 months after chemoradiation and no recurrence has occurred at 20 months since chemoradiation. Conclusion: Radiotherapy or chemoradiotherapy can be an alternative locoregional therapy to surgery for solitary skeletal muscle metastasis.

UR - http://www.scopus.com/inward/record.url?scp=85031098532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031098532&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12005

DO - 10.21873/anticanres.12005

M3 - Article

C2 - 28982887

AN - SCOPUS:85031098532

VL - 37

SP - 5687

EP - 5691

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -